Can hospitals enjoy medical insurance reimbursement when purchasing osimertinib?

Osimertinib/Tagressa As an effective targeted therapy, it has been approved in many countries around the world for the treatment of EGFR mutant non-small cell lung cancer (NSCLC). In China, the original drug of osimertinib has been officially launched, and as an important anti-cancer drug, it has been included in the scope of medical insurance reimbursement.

In China, the common specifications of osimertinib are80 mg × 30 tablets and 40 mg × 30 tablets, with prices ranging from approximately RMB 4,000 to RMB 6,000 (the specific price may fluctuate depending on the region and drug retailers). Although the drug price of osimertinib is relatively expensive, due to its significant clinical effect and high therapeutic value for patients with advanced lung cancer with positive EGFR mutation, osimertinib has been included in the national medical insurance catalog, and patients can enjoy partial medical insurance reimbursement when purchasing this drug.

According to different medical insurance policies, patients may enjoy certain cost reductions when purchasing osimertinib. Medical insurance reimbursement usually varies based on the specific policies of the patient's region and the level of medical insurance reimbursement. Some patients may be required to pay a self-pay portion, especially if they do not fully qualify for Medicare reimbursement. The out-of-pocket portion after medical insurance reimbursement usually depends on the patient's medical insurance type, reimbursement ratio, and other personal health conditions.

Therefore, when purchasing osimertinib in a hospital, first consult the local medical insurance department and other places to find out whether it meets the medical insurance reimbursement standards and the specific reimbursement ratio. If eligible for medical insurance reimbursement, patients will be able to alleviate some of their financial burden, making treatment more accessible.

In short, osimertinib not only brings hope of cure to patients through effective targeted therapy, but also provides strong support for patients' economic burden through medical insurance reimbursement. However, due to changes in drug prices and medical insurance policies, patients should maintain good communication with doctors and medical insurance institutions during the treatment process to ensure that they receive the latest treatment options and cost support.

Reference materials:https://go.drugbank.com/drugs/DB09330